Publication year
2015Source
Trends in Pharmacological Sciences, 36, 4, (2015), pp. 189-195ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Rheumatology
Journal title
Trends in Pharmacological Sciences
Volume
vol. 36
Issue
iss. 4
Page start
p. 189
Page end
p. 195
Subject
Radboudumc 5: Inflammatory diseases RIMLS: Radboud Institute for Molecular Life SciencesAbstract
Rheumatoid arthritis (RA) is an autoimmune disease that leads to inflammation and destruction of synovial joints. Despite the broad spectrum of antirheumatic drugs, this heterogeneous disease is still not well controlled in up to 30% of patients. Here, we discuss two pathways that are regarded as interesting novel therapeutic targets in the field of rheumatology: the Janus kinase (JAK) pathway and the T helper-17 (Th17) pathway [including interleukin (IL)-17, IL-21, IL-22, and granulocyte-macrophage colony-stimulating factor (GM-CSF)]. We also review the therapy potential of biologicals and small-molecule inhibitors blocking these pathways. Advances in combination therapy in addition to progress in biomarker screening will help us to further achieve effective and personalized healthcare for patients with RA.
This item appears in the following Collection(s)
- Academic publications [204994]
- Faculty of Medical Sciences [81051]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.